Looking Ahead To 2012: ACOs Get In Gear, Accelerating The Need to Prove Biopharma Products' Overall Value In Health Care
Thirty-two "Pioneer" accountable care organizations began operations with the new year.
You may also be interested in...
Drug company sales forces have an opportunity to play a larger role in assisting ACO organizations to achieve their goals, Pfizer’s John Zgombic pointed out, because focusing only on a transactional sale with the physician “is no longer valid.”
The value of medicine was a key theme at Citigroup’s Global Healthcare conference in New York, where top executives from Bristol, Sanofi, Pfizer and Lilly, including J&J’s CEO Alex Gorsky participated in Q&As with analysts and attendees.
Updates on Medicare’s ACO program, drug spending trends and Medicare coverage of IVIG.